The first report of potential synergism between BET inhibition and PARPi was based on a drug combination screen testing PARPi olaparib in BRCA-wildtype triple negative breast (TNBC), ovarian, and prostate cancer in combination with 20 well-characterized epigenetic modulators across seven classes, demonstrating synergism for all tested BET inhibitors (BETi) [82]. This evidence concerns the gene DNER and Familial prostate cancer.